文章：

三阴性乳腺癌内在性FTSJ1促进肿瘤进展并减弱CD8+ T细胞浸润

Triple-Negative Breast Cancer Intrinsic FTSJ1 Favors Tumor Progression and Attenuates CD8+ T Cell Infiltration

原文发布日期：31 January 2024

DOI: 10.3390/cancers16030597

类型: Article

开放获取: 是

英文摘要：

FtsJ RNA 2′-O-methyltransferase 1 (FTSJ1) is a member of the methyltransferase superfamily and is involved in the processing and modification of ribosomal RNA. We herein demonstrate that FTSJ1 favors TNBC progression. The knockdown of FTSJ1 inhibits TNBC cell proliferation and development, induces apoptosis of cancer cells, and increases the sensitivity of TNBC cells to T-cell-mediated cytotoxicity. Furthermore, the high expression of FTSJ1 in TNBC attenuates CD8+T cell infiltration in the tumor microenvironment (TME) correlated with poorer prognosis for clinical TNBC patients. In this study, we establish that FTSJ1 acts as a tumor promotor, is involved in cancer immune evasion, and may serve as a potential immunotherapy target in TNBC.

摘要翻译： 

FtsJ RNA 2′-O-甲基转移酶1（FTSJ1）是甲基转移酶超家族成员，参与核糖体RNA的加工与修饰。本研究证实FTSJ1促进三阴性乳腺癌进展。敲低FTSJ1可抑制三阴性乳腺癌细胞增殖与生长，诱导癌细胞凋亡，并增强三阴性乳腺癌细胞对T细胞介导的细胞毒作用的敏感性。此外，FTSJ1在三阴性乳腺癌中的高表达会减弱肿瘤微环境中CD8+T细胞浸润，这与临床三阴性乳腺癌患者不良预后相关。本研究确立了FTSJ1作为肿瘤促进因子参与癌症免疫逃逸的作用机制，提示其可能成为三阴性乳腺癌的潜在免疫治疗靶点。

原文链接：

Triple-Negative Breast Cancer Intrinsic FTSJ1 Favors Tumor Progression and Attenuates CD8+ T Cell Infiltration